pharmacopeia
GET
/api/v1/drug/budesonide
2D structure
(1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-propyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one
SMILES CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@@]5([C@H]4[C@H](C[C@@]3([C@@]2(O1)C(=O)CO)C)O)C
InChIKey VOVIALXJUBGFJZ-KWVAZRHASA-N

Mechanism of action

Sourced from openFDA

Mechanism-of-action classes: Corticosteroid Hormone Receptor Agonists; Glucocorticoid Receptor Agonists.

Corticosteroid Hormone ReceptorGlucocorticoid Receptor

Indications

Sourced from openFDA
  • Use s Temporarily relieves these symptoms of hay fever or other upper respiratory allergies: • nasal congestion • runny nose • itchy nose • sneezing

Dosage & administration

Sourced from openFDA

Directions Read insert (inside package) on how to: get a new bottle ready (primed) before first use prime bottle again if not used for two days use the spray clean the spray nozzle ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER adults and children 12 years of age and older once daily, spray 2 times into each nostril while sniffing gently once your allergy symptoms improve, reduce to 1 spray in each nostril per day CHILDREN 6 TO UNDER 12 YEARS OF AGE the growth rate of some children may be slower while using this product. Talk to your child’s doctor if your child needs to use the spray for longer than two months a year children 6 to under 12 years of age an adult should supervise use once daily, spray 1 time into each nostril while sniffing gently if allergy symptoms do not improve, increase to 2 sprays in each nostril per day. Once allergy symptoms improve, reduce to 1 spray in each nostril per day children under 6 years of age do not use do not use more than directed if you forget a dose, do not double the next dose do not spray into eyes or mouth if allergy symptoms do not improve after two weeks, stop using and talk to a doctor do not use for the common cold shake well before each use

Warnings & precautions

Sourced from openFDA

Do not use in children under 6 years of age if you have ever had an allergic reaction to any of the ingredients Ask a doctor before use if you have had recent nose ulcers or nose surgery have had a nose injury that has not healed are using a steroid medicine for asthma, allergies or skin rash have an eye infection have or had glaucoma or cataracts When using this product the growth rate of some children may be slower some symptoms may get better on the first day of treatment. It may take up to two weeks of daily use to feel the most symptom relief. do not share this bottle with anyone else as this may spread germs remember to tell your doctor about all the medicines you take, including this one Stop use and ask a doctor if you have, or come into contact with someone who has, chickenpox, measles or tuberculosis you have or develop symptoms of an infection such as persistent fever you have any change in vision you have severe or frequent nosebleeds If pregnant or breast-feeding , ask a health professional before use. Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away (1-800-222-1222).

Approval history

Sourced from openFDA
  • Aug 8, 2000NDANDA020929Astrazeneca
  • Oct 2, 2001NDANDA021324Padagis Us
  • Jul 12, 2006NDANDA021949Cheplapharm
  • Jul 21, 2006NDANDA021929Astrazeneca
  • Jan 14, 2013NDANDA203634Salix
  • Oct 7, 2014NDANDA205613Salix
  • Jul 23, 2020NDANDA212122Astrazeneca Ab
  • Dec 15, 2021NDANDA215935Calliditas

Literature

View JSON

Recent PubMed references pinned to Budesonide as a MeSH major topic. Citations link to pubmed.ncbi.nlm.nih.gov.

Clinical trials

View JSON

The 10 most recently updated of 697 ClinicalTrials.gov registrations naming Budesonide as an intervention. Registration is not evidence of efficacy or safety — reference crosswalk only.

Pharmacogenomics

View JSON

CPIC-curated drug–gene pairs for Budesonide. Levels describe the strength of curated evidence and guideline status — never a recommendation to test or to adjust therapy.

  • CRHR1CPIC D (provisional)

Structural analogs

View JSON

Ranked by 2D fingerprint (Tanimoto) similarity over PubChem structures. Structural proximity only — not a claim of therapeutic equivalence.

Frequently asked questions

How does Budesonide work?
Mechanism-of-action classes: Corticosteroid Hormone Receptor Agonists; Glucocorticoid Receptor Agonists.
What is Budesonide used for?
According to FDA labeling, Budesonide carries indications including: Use s Temporarily relieves these symptoms of hay fever or other upper respiratory allergies: • nasal congestion • runny nose • itchy nose • sneezing. This is a reference summary of labeled uses, not medical advice or a treatment recommendation.
What class of drug is Budesonide?
Budesonide is classified as Corticosteroids, Corticosteroids acting locally, Corticosteroids, potent (group III), Glucocorticoids, Corticosteroid, Corticosteroid Hormone Receptor Agonists, Glucocorticoid Receptor Agonists, Decreased Cellular Migration, Decreased Glucocorticoid Secretion, Decreased Lysosomal Function, Decreased Protein Synthesis.
What are the brand names for Budesonide?
Budesonide is marketed under brand names including Airsupra, Breyna, Breztri, Entocort, Eohilia, Ortikos, Pulmicort, Rhinocort.
Note. Data for budesonide is illustrative MVP content compiled from public sources. pharmacopeia is for educational and informational use only and is not a substitute for professional medical advice.

Search pharmacopeia

Search drugs, classes, and ingredients